Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor

被引：0
|
作者：
Vermeire, S. [1 ]
De Hertogh, G. [2 ]
Chen, G. [3 ]
French, D. [4 ]
Huntzicker, E. [4 ]
Van der Aa, A. [5 ]
Van Kaem, T. [5 ]
Harrison, P. [5 ]
Tasset, C. [5 ]
Galien, R. [6 ]
Pan, Y. [4 ]
Feagan, B. [7 ]
Sandborn, W. [8 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol, Leuven, Belgium
[2] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium
[3] Gilead Sci, Dept Biostat, Foster City, CA USA
[4] Gilead Sci, Biomarker Sci, Foster City, CA USA
[5] Galapagos NV, Mechelen, Belgium
[6] Galapagos SASU, Romainville, France
[7] Robarts Res Inst, London, ON, Canada
[8] Univ Calif San Diego, Div Gastroenterol, San Diego, CA 92103 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP033
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 43 条
  • [1] FILGOTINIB (GLPG0634, GS-6034), A JAK-1 SELECTIVE INHIBITOR, SIGNIFICANTLY REDUCES GUT TISSUE PSTAT3 IN CROHN'S DISEASE PATIENTS
    Sandborn, William J.
    Feagan, Brian G.
    De Hertogh, Gert
    Chen, Guang
    French, Dorothy M.
    Huntzicker, Erik G.
    Van der Aa, Annegret
    Van Kaem, Tim
    Harrison, Pille
    Tasset, Chantal T.
    Galien, Rene
    Pan, Yang
    Vermeire, Severine
    GASTROENTEROLOGY, 2017, 152 (05) : S602 - S602
  • [2] GLPG0634M1, A MAJOR METABOLITE OF THE JAK1-SELECTIVE INHIBITOR GLPG0634, IS ALSO JAK1-SELECTIVE AND EFFICIENT IN THE RAT CIA MODEL
    Belleville-Da-Costa, C.
    Merciris, D.
    Vayssiere, B.
    Houvenaghel, N.
    Monjardet, A.
    Lepescheux, L.
    Dupont, S.
    Christophe, T.
    Borgonovi, M.
    Clement-Lacroix, P.
    Menet, C.
    Van Rompaey, L.
    Brys, R.
    Galien, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 226 - 227
  • [3] Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
    Kavanaugh, A.
    Kremer, J.
    Ponce, L.
    Cseuz, R.
    Reshetko, O. V.
    Stanislavchuk, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1009 - 1019
  • [4] IDENTIFICATION OF A GENE SIGNATURE AND RESPONSE BIOMARKERS IN CIRCULATING LEUKOCYTES OF RA PATIENTS AFTER TREATMENT WITH THE JAK1-SELECTIVE INHIBITOR FILGOTINIB (GLPG0634)
    Ongenaert, M.
    Dupont, S.
    Vayssiere, B.
    Meuleners, L.
    Brys, R.
    Galien, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1068 - 1068
  • [5] Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor
    Florence, Namour
    Fagard, Liesbeth
    Van der Aa, Annegret
    Goss, Sandy
    Harrison, Pille
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [6] 4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL
    Galien, Rene
    Harrison, Pille
    Brys, Reginald
    Van der Aa, Annegret
    van't Klooster, Gerben
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
    Westhovens, R.
    Taylor, P. C.
    Alten, R.
    Pavlova, D.
    Enriquez-Sosa, F.
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 998 - 1008
  • [8] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Florence Namour
    Paul Matthias Diderichsen
    Eugène Cox
    Béatrice Vayssière
    Annegret Van der Aa
    Chantal Tasset
    Gerben Van‘t Klooster
    Clinical Pharmacokinetics, 2015, 54 : 859 - 874
  • [9] FILGOTINIB (GLPG0634), A SELECTIVE JAK1 INHIBITOR, SHOWS SIMILAR PK AND PD PROFILES IN JAPANESE AND CAUCASIAN HEALTHY VOLUNTEERS
    Namour, F.
    Vayssiere, B.
    Galien, R.
    Fagard, L.
    Van der Aa, A.
    Harrison, P.
    Tasset, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1063 - 1064
  • [10] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Namour, Florence
    Diderichsen, Paul Matthias
    Cox, Eugene
    Vayssiere, Beatrice
    Van der Aa, Annegret
    Tasset, Chantal
    Van't Klooster, Gerben
    CLINICAL PHARMACOKINETICS, 2015, 54 (08) : 859 - 874
12345